**Name of Journal:** *World Journal of Anesthesiology*

**Manuscript NO:** 57157

**Manuscript Type:** EDITORIAL

**Low dose corticosteroids in COVID-19 with refractory shock: We are not sure?**

Omar AS. COVID-19, low dose corticosteroids, shock

Amr Salah Omar

**Amr Salah Omar,** Department of Cardiothoracic Surgery/Cardiac Anaesthesia and ICU, Heart Hospital, Hamad Medical Corporation, Doha 3050, Qatar

**Amr Salah Omar,** Department of Critical Care Medicine, Beni Suef University, Beni Suef 71515, Egypt

**Amr Salah Omar,** Department of Medicine, Weill Cornell Medical College in Qatar, Doha 3050, Qatar

**Author contributions:** Omar AS solely contributed to this manuscript.

**Corresponding author: Amr Salah Omar, MBChB, MD, MSc, PhD, Professor,** Department of Cardiothoracic Surgery/Cardiac Anaesthesia and ICU, Heart Hospital, Hamad Medical Corporation, Doha 3050, Qatar. a\_s\_omar@yahoo.com

**Received:** May 27, 2020

**Revised:** July 22, 2020

**Accepted:** August 15, 2020

**Published online:** September 27, 2020

**Abstract**

Low dose corticosteroids to adult patients with coronavirus disease 2019 (COVID-19) and refractory shock was given some evidence, the evidence was of low quality given particularly for shock-reversal. Evidence. However bacterial sepsis may not provide a similar evidence like in a viral related one. We think that suggesting steroids for COVID-19 may not be adequate in the current time and future data analysis should be directed to find possible evidence in a matched population

**Key Words:** Corticosteroids; Sepsis; Shock; COVID-19; Refractory; Outcome

**Citation:** Omar AS. Low dose corticosteroids in COVID-19 with refractory shock: We are not sure? *World J Anesthesiol* 2020; 9(1): 1-2

**URL:** https://www.wjgnet.com/2218-6182/full/v9/i1/1.htm

**DOI:** https://dx.doi.org/10.5313/wja.v9.i1.1

**Core Tip:** We think that suggesting steroids for coronavirus disease 2019 may not be adequate in the current time and future data analysis should be directed to find possible evidence in a matched population.

**INTRODUCTION**

 With great interest we followed the recent guidelines for managing critically ill adult patients with coronavirus disease 2019 (COVID-19) that was released from the Surviving Sepsis Campaign. The writing group gave a weak recommendation for giving low dose corticosteroids to adult patients with COVID-19 and refractory shock, the evidence was of low quality given particularly for shock-reversal[1]. The utility of low dose corticosteroids plus fludrocortisone therapy were presented in a study by Annane *et al*[2], the authors found a lower 90-days all-cause mortality in the corticosteroids treated group when compared with placebo confirming adrenocortical insufficiency in these patients.

    We argue that the given evidence in bacterial sepsis may not provide a similar one in a viral related one. Delayed viral redemption, diabetes, psychosis, and avascular necrosis could exist, plus absence of survival benefit which was found in a systemic review analyzed observational studies of corticosteroids in patients with severe acute respiratory syndrome related to viral invasion[3]. In a recent study by Arabi *et al*[4], done on 309 patients infected with middle east respiratory syndrome (MERS), the authors did not find a mortality advantage in the corticosteroid treated population after utilizing an adjusted time varying statistical approach for confounders. Moreover, they observed delayed clearance of MERS coronavirus RNA.

     In many cases of viral invasion, the reason for shock remains unclear, however it could be due to viral myocarditis or stress cardiomyopathy where corticosteroids could be of no value or adding additional harm to this dilemma.[5]  In Annane’s trial,[2] adequacy of the starting antimicrobial regimen was judged first according to insulting pathogen sensitivity and the site of infection in 96.2% and 96.9% of the patients who received antimicrobials either placebo or corticosteroids respectively. The later coverage does not exist till now for COVID-19.

**CONCLUSION**

We think that the indirect evidence used for suggesting steroids for COVID-19 may not be adequate in the current time and future data analysis should be directed to find possible evidence in a matched population.

**REFERENCES**

1 **Alhazzani W**, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A, Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M, Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti JE, Citerio G, Baw B, Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). *Intensive Care Med* 2020; **46**: 854-887 [PMID: 32222812 DOI: 10.1007/s00134-020-06022-5]

2 **Annane D**, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, François B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Bohé J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E; CRICS-TRIGGERSEP Network. Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. *N Engl J Med* 2018; **378**: 809-818 [PMID: 29490185 DOI: 10.1056/NEJMoa1705716]

3 **Stockman LJ**, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006; **3**: e343 [PMID: 16968120 DOI: 10.1371/journal.pmed.0030343]

4 **Arabi YM**, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A, Almotairi A, Al Khatib K, Alraddadi B, Shalhoub S, Abdulmomen A, Qushmaq I, Mady A, Solaiman O, Al-Aithan AM, Al-Raddadi R, Ragab A, Balkhy HH, Al Harthy A, Deeb AM, Al Mutairi H, Al-Dawood A, Merson L, Hayden FG, Fowler RA; Saudi Critical Care Trial Group. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. *Am J Respir Crit Care Med* 2018; **197**: 757-767 [PMID: 29161116 DOI: 10.1164/rccm.201706-1172OC]

5 **Buzon J**, Roignot O, Lemoine S, Perez P, Kimmoun A, Levy B, Novy E. Takotsubo Cardiomyopathy Triggered by Influenza A Virus. *Intern Med* 2015; **54**: 2017-2019 [PMID: 26278294 DOI: 10.2169/internalmedicine.54.3606]

**Footnotes**

**Conflict-of-interest statement:** The author has no conflicts of interest to declare.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** May 27, 2020

**First decision:** July 21, 2020

**Article in press:** August 15, 2020

**Specialty type:** Critical care medicine

**Country/Territory of origin:** Qatar

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Kasztelan-Szczerbinska B, Wang X **S-Editor:** Ma YJ **L-Editor: P-Editor:** Li JH